2024-07-25 12:24:02
A new beacon of hope has emerged for HIV prevention. Recent Phase 3 trial results show that twice-yearly injections of the drug to treat HIV can prevent new infections 100 percent of the time.
at a landmark trial The study, which involved 5,000 young women and girls in South Africa and Uganda, reported no cases of HIV infection among patients who received two shots of lenacapavir, made by drugmaker Gilead.
Participants were randomly assigned to receive either an injection of lenacavir every 26 weeks or a daily oral HIV medication such as emtricitabine-tenofovir alafenamide (F/TAF) or emtricitabine-fumarate Tenofovir disoproxil disoproxil (FTC/TDF). The study was double-blind, so participants did not know which treatment they were receiving.
The results showed that about 2% of people who took the drug daily acquired HIV from an infected partner, underscoring the effectiveness of lenacapavir compared with daily oral medications.
“With zero infections and 100% efficacy, twice-yearly administration of lenapavir has demonstrated its potential as an important new tool to help prevent HIV infection. We look forward to additional results from the ongoing PURPOSE clinical program and continuing Reaching our goal to help end HIV infection. explain Dr. Merdad Parsey, Chief Medical Officer, Gilead Sciences.
About 69% of participants experienced injection site reactions, compared with 35% of the placebo group. However, the researchers reported that no safety issues were found.
Lenacapavir (trade name Sunlenca) has become a prescription drug to treat HIV. Following the successful completion of the PURPOSE 1 trial, researchers are looking forward to results from the PURPOSE 2 trial, which evaluates the effectiveness of twice-yearly injections of lenacavir in preventing HIV in different populations and regions.
“These data confirm that twice-yearly lenapavir for HIV prevention is a breakthrough advance with enormous public health potential. If approved and delivered quickly, cost-effectively, and equitably to those who need or want it “We are all grateful to the thousands of people in South Africa and Uganda who have voluntarily taken part in this initiative,” Sharon Lewin, president of the International AIDS Society (IAS), said in a report. The young women in the study expressed their gratitude. Press Releases.
“Now we eagerly await the results of Aim 2, which is evaluating twice-yearly doses of lenacavir for HIV prevention in other populations and countries. In the meantime, all stakeholders must work together to accelerate equitable access to Provide existing HIV prevention options and do more to prepare for future options, such as lenacapvir for PrEP,” Lewin said.
1721934964
#Trial #results #show #twiceyearly #injections #provide #protection
